ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma

Camilla Krakstad, Ingvild L. Tangen, Erling A. Hoivik, Mari K. Halle, Anna Berg, Henrica M. Werner, Maria B. Ræder, Kanthida Kusonmano, June X Zou, Anne M. Øyan, Ingunn Stefansson, Jone Trovik, Karl Henning Kalland, Hongwu Chen, Helga B. Salvesen

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We have explored the potential for clinical implementation of ATAD2 as a biomarker for aggressive endometrial cancer by investigating to what extent immunohistochemical (IHC) staining for ATAD2 is feasible, reflects clinical phenotype and molecular subgroups of endometrial carcinomas. Increased expression of the ATAD2 gene has been implicated in cancer development and progression in a number of tissues, but few studies have investigated ATAD2 expression using IHC. Here we show that high ATAD2 protein expression is significantly associated with established clinical-pathological variables for aggressive endometrial cancer, also in the subset of estrogen receptor a (ERa) positive tumors. Protein and mRNA expression of ATAD2 were highly correlated (P <0.001), suggesting that IHC staining may represent a more clinically applicable measure of ATAD2 level in routinely collected formalin fixed paraffin embedded specimens. Gene expression alterations in samples with high ATAD2 expression revealed upregulation of several cancer-related genes (B-MYB, CDCs, E2Fs) and gene sets that previously have been linked to aggressive disease and potential for new targeting therapies. Our results support that IHC staining for ATAD2 may be a clinically applicable biomarker reflecting clinical phenotype and targetable alterations in endometrial carcinomas to be further explored in controlled clinical trials.

Original languageEnglish (US)
Pages (from-to)28440-28452
Number of pages13
JournalOncotarget
Volume6
Issue number29
DOIs
StatePublished - 2015

Fingerprint

Endometrial Neoplasms
Staining and Labeling
Biomarkers
Phenotype
Gene Expression
Neoplasm Genes
Controlled Clinical Trials
Centers for Disease Control and Prevention (U.S.)
Estrogen Receptors
Paraffin
Formaldehyde
Neoplasms
Proteins
Up-Regulation
Messenger RNA
Genes
Therapeutics

Keywords

  • ATAD2
  • Biomarker
  • Endometrial cancer
  • Molecular profiling

ASJC Scopus subject areas

  • Oncology

Cite this

Krakstad, C., Tangen, I. L., Hoivik, E. A., Halle, M. K., Berg, A., Werner, H. M., ... Salvesen, H. B. (2015). ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. Oncotarget, 6(29), 28440-28452. https://doi.org/10.18632/oncotarget.4955

ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. / Krakstad, Camilla; Tangen, Ingvild L.; Hoivik, Erling A.; Halle, Mari K.; Berg, Anna; Werner, Henrica M.; Ræder, Maria B.; Kusonmano, Kanthida; Zou, June X; Øyan, Anne M.; Stefansson, Ingunn; Trovik, Jone; Kalland, Karl Henning; Chen, Hongwu; Salvesen, Helga B.

In: Oncotarget, Vol. 6, No. 29, 2015, p. 28440-28452.

Research output: Contribution to journalArticle

Krakstad, C, Tangen, IL, Hoivik, EA, Halle, MK, Berg, A, Werner, HM, Ræder, MB, Kusonmano, K, Zou, JX, Øyan, AM, Stefansson, I, Trovik, J, Kalland, KH, Chen, H & Salvesen, HB 2015, 'ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma', Oncotarget, vol. 6, no. 29, pp. 28440-28452. https://doi.org/10.18632/oncotarget.4955
Krakstad, Camilla ; Tangen, Ingvild L. ; Hoivik, Erling A. ; Halle, Mari K. ; Berg, Anna ; Werner, Henrica M. ; Ræder, Maria B. ; Kusonmano, Kanthida ; Zou, June X ; Øyan, Anne M. ; Stefansson, Ingunn ; Trovik, Jone ; Kalland, Karl Henning ; Chen, Hongwu ; Salvesen, Helga B. / ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. In: Oncotarget. 2015 ; Vol. 6, No. 29. pp. 28440-28452.
@article{1463a4520c40429eb27dfcfebab0fd78,
title = "ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma",
abstract = "We have explored the potential for clinical implementation of ATAD2 as a biomarker for aggressive endometrial cancer by investigating to what extent immunohistochemical (IHC) staining for ATAD2 is feasible, reflects clinical phenotype and molecular subgroups of endometrial carcinomas. Increased expression of the ATAD2 gene has been implicated in cancer development and progression in a number of tissues, but few studies have investigated ATAD2 expression using IHC. Here we show that high ATAD2 protein expression is significantly associated with established clinical-pathological variables for aggressive endometrial cancer, also in the subset of estrogen receptor a (ERa) positive tumors. Protein and mRNA expression of ATAD2 were highly correlated (P <0.001), suggesting that IHC staining may represent a more clinically applicable measure of ATAD2 level in routinely collected formalin fixed paraffin embedded specimens. Gene expression alterations in samples with high ATAD2 expression revealed upregulation of several cancer-related genes (B-MYB, CDCs, E2Fs) and gene sets that previously have been linked to aggressive disease and potential for new targeting therapies. Our results support that IHC staining for ATAD2 may be a clinically applicable biomarker reflecting clinical phenotype and targetable alterations in endometrial carcinomas to be further explored in controlled clinical trials.",
keywords = "ATAD2, Biomarker, Endometrial cancer, Molecular profiling",
author = "Camilla Krakstad and Tangen, {Ingvild L.} and Hoivik, {Erling A.} and Halle, {Mari K.} and Anna Berg and Werner, {Henrica M.} and R{\ae}der, {Maria B.} and Kanthida Kusonmano and Zou, {June X} and {\O}yan, {Anne M.} and Ingunn Stefansson and Jone Trovik and Kalland, {Karl Henning} and Hongwu Chen and Salvesen, {Helga B.}",
year = "2015",
doi = "10.18632/oncotarget.4955",
language = "English (US)",
volume = "6",
pages = "28440--28452",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "29",

}

TY - JOUR

T1 - ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma

AU - Krakstad, Camilla

AU - Tangen, Ingvild L.

AU - Hoivik, Erling A.

AU - Halle, Mari K.

AU - Berg, Anna

AU - Werner, Henrica M.

AU - Ræder, Maria B.

AU - Kusonmano, Kanthida

AU - Zou, June X

AU - Øyan, Anne M.

AU - Stefansson, Ingunn

AU - Trovik, Jone

AU - Kalland, Karl Henning

AU - Chen, Hongwu

AU - Salvesen, Helga B.

PY - 2015

Y1 - 2015

N2 - We have explored the potential for clinical implementation of ATAD2 as a biomarker for aggressive endometrial cancer by investigating to what extent immunohistochemical (IHC) staining for ATAD2 is feasible, reflects clinical phenotype and molecular subgroups of endometrial carcinomas. Increased expression of the ATAD2 gene has been implicated in cancer development and progression in a number of tissues, but few studies have investigated ATAD2 expression using IHC. Here we show that high ATAD2 protein expression is significantly associated with established clinical-pathological variables for aggressive endometrial cancer, also in the subset of estrogen receptor a (ERa) positive tumors. Protein and mRNA expression of ATAD2 were highly correlated (P <0.001), suggesting that IHC staining may represent a more clinically applicable measure of ATAD2 level in routinely collected formalin fixed paraffin embedded specimens. Gene expression alterations in samples with high ATAD2 expression revealed upregulation of several cancer-related genes (B-MYB, CDCs, E2Fs) and gene sets that previously have been linked to aggressive disease and potential for new targeting therapies. Our results support that IHC staining for ATAD2 may be a clinically applicable biomarker reflecting clinical phenotype and targetable alterations in endometrial carcinomas to be further explored in controlled clinical trials.

AB - We have explored the potential for clinical implementation of ATAD2 as a biomarker for aggressive endometrial cancer by investigating to what extent immunohistochemical (IHC) staining for ATAD2 is feasible, reflects clinical phenotype and molecular subgroups of endometrial carcinomas. Increased expression of the ATAD2 gene has been implicated in cancer development and progression in a number of tissues, but few studies have investigated ATAD2 expression using IHC. Here we show that high ATAD2 protein expression is significantly associated with established clinical-pathological variables for aggressive endometrial cancer, also in the subset of estrogen receptor a (ERa) positive tumors. Protein and mRNA expression of ATAD2 were highly correlated (P <0.001), suggesting that IHC staining may represent a more clinically applicable measure of ATAD2 level in routinely collected formalin fixed paraffin embedded specimens. Gene expression alterations in samples with high ATAD2 expression revealed upregulation of several cancer-related genes (B-MYB, CDCs, E2Fs) and gene sets that previously have been linked to aggressive disease and potential for new targeting therapies. Our results support that IHC staining for ATAD2 may be a clinically applicable biomarker reflecting clinical phenotype and targetable alterations in endometrial carcinomas to be further explored in controlled clinical trials.

KW - ATAD2

KW - Biomarker

KW - Endometrial cancer

KW - Molecular profiling

UR - http://www.scopus.com/inward/record.url?scp=84944463891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944463891&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.4955

DO - 10.18632/oncotarget.4955

M3 - Article

C2 - 26308378

AN - SCOPUS:84944463891

VL - 6

SP - 28440

EP - 28452

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 29

ER -